Skip to main content
European Commission logo print header

Fluorescence and Reactive oxygen Intermediates by Neutron Generated electronic Excitation as a foundation for radically new cancer therapies

Project description

A radical neutron therapy for difficult to reach cancers

When cancer is mentioned, we often think of chemotherapy. However, radiotherapy has been a powerful weapon for over a century, employing high doses of ionising radiation to kill cancer cells, or slow down their growth by damaging their DNA. Neutron-based therapies that work primarily through nuclear interactions, have been used to treat radioresistant tumours, but lack cancer-specificity. This may induce damage to healthy tissues and cause new carcinogenesis. Photomedical therapies use light to trigger lethal reactions between light-sensitive compounds and oxygen, targeting cancerous cells. Nevertheless, they lack sufficient penetration depth to reach deep-seated cancers. The EU-funded project FRINGE is developing a new therapeutic approach combining the best of both worlds.

Objective

Deep lying tumours like aggressive brain cancer remain very difficult to treat and existing therapies offer only marginal increase in survival rates. In the case of photomedical therapies they are very effective, but mainly limited by their insufficient depth of light penetration into tissue. Current neutron-based therapies have sufficient penetration depth but suffer from lack of cancer specificity. In FRINGE we propose a genuinely new hybrid-technology. At its heart are chemical agents (photosensitisers - PS) which preferentially accumulate in the tumours especially in brain cancers where the blood brain barrier is compromised. The PSs designed for FRINGE will contain metal centres like Gadolinium (Gd), to enable interaction with incoming neutrons and facilitate the transfer of neutron energy into electron excitation of the PS, confirmed by concomitant fluorescence emission. Interaction with ambient oxygen will generate reactive oxygen species which will kill the tumour cells. The main scientific breakthrough of this project will be to establish experimental proof-of-principle of this novel neutron-activated therapy. FRINGE will combine the advantages of photomedical therapies (no mutagenic radiation) with the advantages of neutron-based therapies (large penetration depth). The externally-applied neutron beam can be energy-tuned to become therapeutic exactly at the depth of the tumour. Exploiting Gd as a contrast agent, FRINGE can also become a theranostic modality by use of magnetic resonance imaging. FRINGE has the potential of causing immunogenic cell death to cancers which could eliminate occult metastasis and act as a ‘cancer vaccine’. The highly interdisciplinary project team comprises world renowned experts from a unique combination of disciplines: Nuclear physicists, synthetic chemists, photochemists, photobiologists, medical physicists, quantum chemists and radio-oncologists will join forces to lay the foundations for a novel, curative cancer therapy.

Call for proposal

H2020-FETOPEN-2018-2020

See other projects for this call

Sub call

H2020-FETOPEN-2018-2019-2020-01

æ

Coordinator

OSLO UNIVERSITETSSYKEHUS HF
Net EU contribution
€ 1 145 618,75
Address
Kirkeveien 166 tarnbygget
0450 Oslo
Norway

See on map

Region
Norge Oslo og Viken Oslo
Activity type
Higher or Secondary Education Establishments
Links
Other funding
€ 0,00

Participants (7)